ICER backs cost-effectiveness of Vascepa, Xarelto; Epizyme's lead drug wins speedy US review
→ Drug cost-effectiveness watchdog ICER on Wednesday unveiled preliminary findings from its draft report on additive cardiovascular disease therapies: Amarin’s $AMRN fish oil pill Vascepa and J&J’s $JNJ blood thinner Xarelto. Findings suggest the therapies offer survival benefit over optimal medical management, the institute said. “Assuming clinical signals…hold for patients treated with these interventions and current net prices, the base-case results suggest that costs for treatment with either rivaroxaban (Xarelto) or icosapent ethyl (Vascepa) would fall below commonly cited thresholds for cost-effectiveness.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.